First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors - Mahalingam, D; Patel, M R; Sachdev, J C (2015)
;33(Suppl):Abstract 2518